NPHC NUTRA PHARMA CORP

Overview and Growth

NUTRA PHARMA CORP generated $257.61K of revenue in fiscal 2025, with net loss of $2.05M and an operating cash outflow of $1.16M. At $257.61K, the top line establishes the operating scale supporting the company’s profit and cash-flow profile. Compared with $246.31K in fiscal 2024, revenue recorded a 4.6% year-over-year increase. The company reported diluted EPS of $0.00, adding a shareholder-level measure to the absolute income figures considered below. Diluted shares averaged 7.78B; this is the reported share base over which the company’s diluted per-share earnings were spread. Diluted shares moved 1.4% from 7.67B in fiscal 2024, leaving the current share base higher year over year. At period end, total assets were $584.56K, framing the scale of the company’s operating and financing commitments. Asset turnover was 0.44x, relating the company’s annual revenue directly to the total assets reported at the period end.

Profitability

After reported cost of revenue, the company retained $196.63K as gross profit before recognizing operating expenses and other items. Gross profit represented 76.3% of revenue, showing how much of the top line remained after direct costs. The reported operating result was an operating loss of $1.46M, reflecting costs that exceeded gross profit. Relative to revenue, the operating deficit measured 567.7%, showing the shortfall after operating costs. The company ended the period with a net loss of $2.05M, extending the operating result through all remaining items. Measured against revenue, the bottom-line deficit represented 794.8% after all recognized items. EBITDA was negative $1.45M, showing a deficit before interest, taxes, depreciation, and amortization. The company reported a pretax loss of $2.05M, before the effect of income taxes. Measured against revenue, the pretax deficit represented 794.8%. The net loss equaled 350.2% of period-end assets, showing the deficit relative to the asset base. The net loss widened to $2.05M from $1.29M in fiscal 2024.

Liquidity and Capital Structure

The company held $584.56K of assets against $17.41M of liabilities and -$16.83M of equity, revealing how the asset base was financed. Equity was negative at -$16.83M, meaning liabilities exceeded the residual book value available to shareholders and weakening balance-sheet resilience. The near-term balance sheet paired $459.58K of current assets with $17.27M of current liabilities at the reporting date. Current assets covered only 0.03x of current liabilities, so current liabilities exceeded current assets at period end. Reported cash and equivalents were $12.18K, separating immediately recognizable cash resources from the rest of the current-asset base. The cash balance equaled 0.1% of current liabilities, showing how much near-term coverage came from cash alone. The company carried $9.76M of total debt at period end, which frames its leverage and debt-service burden. The cash-to-assets relationship was 2.1%, comparing reported cash and equivalents with the full positive asset balance. Compared with $599.50K in fiscal 2024, the current asset base moved 2.5% and finished lower. Cash and equivalents were 66.6% lower than fiscal 2024 cash of $36.45K, showing the year-over-year change in liquid resources.

Cash Flow and Earnings Quality

The company reported an operating cash outflow of $1.16M, rather than cash generation from operations. The company spent $26.05K on capital expenditures while operations also absorbed cash, so both ongoing activity and investment drew on liquidity during the period. Negative free cash flow was $1.19M, leaving a cash deficit after capital spending and reducing financial flexibility. Free-cash-flow margin was -461.9%, reflecting a cash deficit equal to 461.9% of revenue after capital spending. The free-cash-flow deficit equaled 203.6% of total assets, placing the cash shortfall against the company’s resource base. The operating cash outflow widened to $1.16M from $423.96K in fiscal 2024.

Based on the annual report for the fiscal year ending Dec 31, 2025. Analysis generated Oct 21, 2026.